L-Methylfolate
5-MTHF · L-5-MTHF · (6S)-5-methyltetrahydrofolate · levomefolic acid · Metafolin · Quatrefolic · Deplin
Last updated
At a glance
Overview
Why L-Methylfolate Shows Up in Serious Stacks#
L-methylfolate is the bioactive form of folate — the only version that skips the MTHFR bottleneck and enters the one-carbon cycle directly. For the bodybuilding and looksmaxxing community, that translates to one specific, concrete job: controlling homocysteine on oral AAS. 17-alpha-alkylated orals reliably push homocysteine up, which compounds the lipid and endothelial hit you're already taking. Methylfolate, paired with methyl-B12 and P5P, is the cleanest way to keep that marker in range without touching anything hormonal.
Beyond cycle support, it has real utility for MTHFR C677T/A1298C carriers (who convert folic acid poorly), as an SSRI adjunct at the 7.5–15 mg Deplin dose for on-cycle or PCT mood dips, and as the "folate slot" in a hair-retention stack where micronutrient gaps quietly sabotage results. It's non-hormonal, safe for women, OTC, cheap, and one of the few compounds in this catalog with clean retail supply from Thorne, Jarrow, and Pure Encapsulations.
"L-methylfolate at 15 mg/day demonstrated statistically significant greater improvement compared with placebo on both primary and secondary outcome measures in patients with SSRI-resistant MDD." — Papakostas et al., Am J Psychiatry (2012)
In this guide we'll cover the dose ladder from general maintenance (400 mcg) up to the multi-mg homocysteine and mood protocols, how to titrate to avoid overmethylation anxiety, why methyl-B12 is non-negotiable alongside it, how to stack it with TMG and P5P for aggressive homocysteine control on orals, and the bloodwork cadence that tells you it's actually working.
How L-Methylfolate works
L-methylfolate is the bioactive, pre-reduced form of folate — the endpoint of the folate cycle rather than a precursor. Every other folate source (folic acid, food folates, folinic acid) has to be processed through dihydrofolate reductase (DHFR) and then methylated by MTHFR before it can do anything biological. L-methylfolate skips that entire assembly line and walks straight into the one-carbon cycle, which is why it works in people whose MTHFR activity is genetically compromised and why it crosses into the CNS.
Bypassing the MTHFR Bottleneck#
The C677T polymorphism in the MTHFR gene drops enzyme activity to roughly 30% of wild-type in homozygotes and around 65% in heterozygotes. That means folic acid and dietary folate pile up upstream while the active 5-MTHF pool runs low — the classic "taking folate and still deficient" picture on bloodwork. L-methylfolate is the product of that reaction, so genotype becomes irrelevant at the absorption stage.
"[6S]-5-methyltetrahydrofolate led to higher plasma folate concentrations than folic acid in women, especially in those with the MTHFR 677TT genotype, confirming that this direct form bypasses the genetic bottleneck." — Prinz-Langenohl R, et al. British Journal of Pharmacology, 2009
Practical payoff: anyone with a known MTHFR variant — and that's a meaningful chunk of Northern European, Hispanic, and East Asian populations — gets a usable folate pool without needing to megadose folic acid and hope for the best.
Homocysteine Remethylation#
This is the mechanism that matters most for users on oral AAS. L-methylfolate donates its methyl group to cobalamin-dependent methionine synthase, which converts homocysteine back into methionine, which then feeds SAMe production. When that pathway is under-supplied, homocysteine accumulates — and homocysteine is an independent vascular risk marker that damages endothelium and accelerates atherosclerosis.
"The significant elevation in plasma homocysteine concentrations in AAS users suggests a potential mechanism by which cardiovascular risk is increased in this cohort." — Graham MR, et al. British Journal of Sports Medicine, 2006
"Administration of 5-methyltetrahydrofolate was shown to be as effective as folic acid in lowering plasma homocysteine concentrations in patients with coronary artery disease." — Willems FF, et al. British Journal of Pharmacology, 2004
Oral 17-alpha-alkylated compounds (stanozolol, oxandrolone, superdrol, tbol) reliably push homocysteine up, compounding the lipid and blood-pressure damage they already cause. Methylfolate + methyl-B12 + P5P is the direct mechanistic answer. Add TMG if levels stay stubborn — betaine provides an MTHFR-independent remethylation route via BHMT.
SAMe Production and Monoamine Synthesis#
Methionine produced from the remethylation step above is the substrate for SAMe (S-adenosylmethionine), the body's universal methyl donor. SAMe is required for regeneration of tetrahydrobiopterin (BH4), which is the rate-limiting cofactor for tyrosine hydroxylase and tryptophan hydroxylase — the enzymes that make dopamine, norepinephrine, and serotonin.
This is the mechanistic basis for the 15 mg/day adjunct protocol in SSRI-resistant depression:
"This study demonstrates that adjunctive L-methylfolate at 15 mg/day demonstrated statistically significant greater improvement compared with placebo on both primary and secondary outcome measures in patients with SSRI-resistant MDD." — Papakostas GI, et al. American Journal of Psychiatry, 2012
For the physique-focused audience, the relevant translation is PCT mood support and on-cycle dysphoria. When estrogen is mismanaged or when the HPTA is coming back online, monoamine output takes a hit. A functioning methylation cycle gives antidepressants — or endogenous monoamine production — better raw material to work with.
DNA Methylation, Nucleotide Synthesis, and Red Cell Production#
Folate cofactors are required for thymidylate and purine synthesis (i.e. making DNA) and for methylation of DNA and histones — the epigenetic layer that controls which genes are on or off. In practice this is why folate deficiency manifests as megaloblastic anemia first: rapidly dividing tissues (bone marrow, gut epithelium) fail when nucleotide supply drops.
"L-5-methyltetrahydrofolate demonstrated comparable or superior bioavailability to folic acid and efficiently raised plasma and red blood cell folate levels, regardless of genotype." — Pietrzik K, et al. Clinical Pharmacokinetics, 2010
For users, this is the "baseline" mechanism — it's why methylfolate fits into a hair stack (follicle cells are among the fastest-dividing in the body), why it's the correct folate for pre-conception protocols in men coming off cycle, and why RBC folate rather than plasma folate is the lab marker that reflects true status. Plasma 5-MTHF clears in hours; the red-cell pool takes 8–12 weeks to plateau, so dose for the long-term pool and don't chase acute bloodwork changes.
The Methyl-Trap and Why B12 Is Non-Negotiable#
Methionine synthase — the enzyme that uses 5-MTHF to remethylate homocysteine — is cobalamin-dependent. Without adequate B12, 5-MTHF enters cells but can't hand off its methyl group, and the folate cycle stalls with everything trapped in the methyl form. This is the "methyl trap," and it's the reason supplementing folate alone can correct the megaloblastic anemia of B12 deficiency on bloodwork while the neurologic damage from that deficiency silently progresses.
Translation: always run methylfolate with methylcobalamin, and confirm B12 status on labs before pushing into the multi-mg range. This is non-negotiable. The rest of the mechanism — homocysteine control, SAMe production, monoamine support — collapses without B12 in the picture.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.4–1 mg | Once daily | Documented entry-level range |
| Mid | 1–5 mg | Once daily | Most commonly studied range |
| High | 7.5–15 mg | Once daily | Dose in the AM with food. Titrate up from 1 mg to gauge overmethylation sensitivity before pushing into the multi-mg range. |
Cycle length & outcomes
Documented cycle
8–52 weeks
Plateau after
12 wks
Cycle Length & Onset#
L-methylfolate isn't a "cycle" compound in the traditional sense — it's a cofactor you run alongside whatever else you're doing. There's no receptor downregulation, no HPTA suppression, no tolerance curve. But onset timing and dose matter, and the right length depends on what you're actually targeting.
The key timing reality: plasma 5-MTHF peaks in 1–2 hours, but red blood cell folate takes 8–12 weeks to plateau. You're dosing for the RBC pool, not the plasma spike. This is why one-week trials tell you nothing and why serious users commit to a minimum 8-week run before judging effect.
Dose Ladder by Goal#
| Goal | Cycle Length | Daily Dose |
|---|---|---|
| General methylation support (B-complex slot) | 8–12+ weeks, ongoing | 0.4–1 mg |
| MTHFR C677T / A1298C rescue | Indefinite | 1–5 mg |
| Homocysteine control on oral AAS | Duration of oral + 2 weeks | 5–15 mg |
| SSRI-resistant mood / PCT dysphoria | 8–12 weeks minimum | 7.5–15 mg |
| Hair stack adjunct | Ongoing | 0.8–1 mg |
| Pre-conception sperm quality cleanup | 12+ weeks pre-TTC | 1 mg |
Titration, Not Loading#
There is no loading phase. There's a titration phase, and skipping it is the single most common mistake at multi-mg doses.
Start at 1 mg/day in the AM with food. Hold for 5–7 days. If tolerated (no anxiety, jaw tension, insomnia, or racing thoughts), step up to 2–3 mg, then 5 mg, then 7.5–15 mg if the indication warrants it. COMT slow-metabolizers and users sensitive to stimulants are the ones who get hit hardest by overmethylation — for them, the sweet spot often lives at 1–3 mg, not 15.
If overmethylation symptoms appear, niacin 50–100 mg acutely burns methyl groups and blunts the effect within an hour. Useful rescue tool to know about.
No taper required coming off. You can stop cold — RBC folate will simply drift back toward baseline over 2–3 months.
Bloodwork Cadence#
Methylfolate is one of the few supplements where bloodwork actually tells you something actionable. Standard 8–12 week cycle panel for physique-focused users should include:
- Homocysteine — the primary target. Aim for 6–8 µmol/L. Above 10 means your stack isn't adequate; above 15 is a cardiovascular flag, especially on orals.
- Serum B12 and RBC folate — confirm you're not masking a B12 deficit and that you're actually raising the folate pool.
- MCV (on standard CBC) — elevated mean corpuscular volume can hint at functional folate or B12 deficiency before serum markers move.
"The significant elevation in plasma homocysteine concentrations in AAS users suggests a potential mechanism by which cardiovascular risk is increased in this cohort." — Graham MR et al., British Journal of Sports Medicine (2006)
This is the core rationale for checking homocysteine on every oral cycle. If you're running tbol, var, superdrol, or winstrol and not tracking this marker, you're missing a major piece of the cardiovascular picture.
Onset Timing by Use Case#
- Homocysteine reduction: measurable at 4 weeks, near-maximal by 8–12 weeks.
- Mood / cognitive effects: reported within 2–4 weeks at 7.5–15 mg; the Papakostas trials ran 60 days to separate from placebo.
- Hair / skin / general support: 8–12 weeks before you'd expect to see any confounder-level benefit — and honestly, this one is more about removing a micronutrient deficit than adding a positive signal.
"Adjunctive L-methylfolate at 15 mg/day demonstrated statistically significant greater improvement compared with placebo on both primary and secondary outcome measures in patients with SSRI-resistant MDD." — Papakostas GI et al., American Journal of Psychiatry (2012)
Long-Term Use#
Unlike most compounds on this site, methylfolate is explicitly designed for indefinite use. MTHFR variants don't go away, and the homocysteine benefit on chronic TRT or serial oral cycles is a long-game play. The 52-week upper bound in the scalars reflects practical review cadence, not a pharmacological limit — recheck bloodwork annually, adjust the dose to keep homocysteine in range, and keep methyl-B12 in the stack the entire time.
Risks & mistakes
Common (most users)#
- Overmethylation symptoms — anxiety, irritability, jaw tension, insomnia, racing thoughts, or a "wired" feeling, most often seen when users jump straight to 7.5–15 mg. Titrate from 1 mg and step up weekly. If symptoms hit acutely, 50–100 mg of niacin (nicotinic acid) will consume excess methyl groups and blunt the effect within an hour. Slow COMT metabolizers are more prone to this and usually land in the 1–5 mg range.
- Mild GI upset — occasional nausea or bloating. Take with food in the AM; split the dose if running multi-mg.
- Headache — usually overmethylation-adjacent or dehydration. Back off 50% and reassess.
- Sleep disruption — dose in the morning, never evening. Methylfolate can be mildly activating in sensitive users.
Uncommon (dose-dependent or individual)#
- Masked B12 deficiency — folate at any meaningful dose corrects the megaloblastic anemia of B12 deficiency while neurologic damage (paresthesias, ataxia, cognitive changes) progresses silently. Always co-dose methylcobalamin 1 mg/day and check serum B12 on your standard panel. This is the single most important mitigation on the entire page.
- Paradoxical low mood or blunting — some users feel worse at 15 mg than at 1 mg, usually because SAMe pressure unmasks a B6, B12, or magnesium shortfall. Drop to 1–5 mg, complete the B-stack (methyl-B12 + P5P + magnesium), and re-titrate.
- Antiepileptic interaction — folate can lower plasma levels of phenytoin, carbamazepine, and valproate. If you're on any of these, the dose needs to be coordinated with the prescriber; don't freelance.
- Unmetabolized folic acid interference — if you're still pulling folic acid from a fortified multi, cereal, or pre-workout, it competes at the folate receptor and muddies results. Audit labels and cut the folic acid sources.
Rare but serious#
- Progression of undiagnosed B12-deficiency neuropathy — the serious form of the masking issue above. Warning signs: numbness/tingling in hands or feet, balance problems, memory fog that doesn't fit context. Stop and get serum B12, MMA, and holotranscobalamin run.
- Possible promotion of pre-existing neoplasia — very high folate intake in individuals with established neoplastic lesions is debated in the oncology literature. Not a concern for healthy users; anyone with an active or recent cancer history should keep dosing to RDA replacement (400–800 mcg) and clear multi-mg use with oncology.
- Serotonergic overshoot on MAOI co-administration — theoretical, mechanistically plausible given 5-MTHF's role in monoamine synthesis via BH4. Treat as a hard contraindication (below).
Hard contraindications#
- Methotrexate, pyrimethamine, or trimethoprim therapy — these drugs work by antagonizing folate. Supplementing methylfolate directly undermines their antineoplastic / antimicrobial action. Do not stack.
- MAOI therapy — avoid the 7.5–15 mg mood-adjunct range. Additive monoamine load is not a risk worth taking.
- Untreated / undiagnosed B12 deficiency — correct B12 status first, then add folate. Never the other way around.
- Active malignancy — defer to oncology on any dose above RDA replacement.
Gender, PCT, and fertility notes#
Methylfolate is non-hormonal, has no HPTA effect, and requires no PCT adjustment — the dose does not change between a blast, a cruise, and time off. Same protocol for men and women.
For women, 800 mcg/day of L-methylfolate is the preferred pre-conception and pregnancy folate source, especially in MTHFR C677T or A1298C carriers, where it outperforms folic acid on plasma folate (Prinz-Langenohl et al., 2009).
"[6S]-5-methyltetrahydrofolate led to higher plasma folate concentrations than folic acid in women, especially in those with the MTHFR 677TT genotype, confirming that this direct form bypasses the genetic bottleneck." — Prinz-Langenohl et al., Br J Pharmacol (2009)
For men running a pre-conception cleanup after AAS, 1 mg/day alongside methyl-B12, zinc, and CoQ10 for 3+ months is the standard protocol — folate status is a documented input to sperm DNA integrity, and it's a cheap box to tick.
Overall, methylfolate is one of the safer entries in the cycle-support toolkit: no HPTA suppression, no liver or lipid hit, no controlled-substance status, and the two real pitfalls — overmethylation and B12 masking — are both trivially mitigated with titration and a methyl-B12 co-dose.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.05 | ×1.00 | ×1.20 |
FAQ — L-Methylfolate
Research & citations
5 studies cited on this page.
Conclusion
L-methylfolate is the go-to folate for anyone dealing with elevated homocysteine, MTHFR polymorphisms, or looking to tighten up methylation status on cycle — and it does so with exceptional oral bioavailability.
Key takeaways:
- Standard dose: 1–5 mg daily for most stacking protocols; titrate from 1 mg to assess tolerance
- Multi-mg dosing (7.5–15 mg) is reserved for SSRI-resistant depression or stubbornly high homocysteine
- Always pair with methylcobalamin (B12) to avoid masking deficiency; add P5P (B6) and TMG (betaine) for max homocysteine control
- Oral and sublingual dosing are equally effective — no need to overthink route
- Blood levels and results plateau over 8–12 weeks, so be patient with cycle length
- Avoid stacking with methotrexate or in the context of untreated B12 deficiency
If you want one supplement that reliably covers folate demands, bypasses genetic bottlenecks, and slots seamlessly into any cycle-support stack, L-methylfolate is the right move.